C1-esterase inhibitor infusion increases survival rates for patients with sepsis*

Critical Care Medicine

Volumn 40, Issue 3, 2012, Pages 770-777

  Igonin, Anton A ^a   Protsenko, Denis N ^b   Galstyan, Gennadiy M ^c   Vlasenko, Alexey V ^d   Khachatryan, Nana N ^e   Nekhaev, Igor V ^f   Shlyapnikov, Sergey A ^g   Lazareva, Natalya B ^a   Herscu, Paul ^h  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Intensive Care Unit   (Russian Federation)

^c NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^d Intensive Care Unit   (Russian Federation)

^e A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^f N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^g Institute of Emergency Care   (Russian Federation)

^h Research Division   (United States)

Author keywords

C1 esterase inhibitor; complement activation; inflammation; kallikrein kinin system; sepsis; systemic inflammation

Indexed keywords

BICIZAR; C REACTIVE PROTEIN; CARBAPENEM DERIVATIVE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INFLAMMATION; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEPSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SEPSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84857570115     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318236edb8     Document Type: Article

References (33)

1. Cinel I, Opal SM: Molecular biology of inflammation and sepsis: A primer. Crit Care Med 2009;37:291-304
2. Scholz W, McClurg MR, Cardenas GJ, et al: C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol 1990;57:297-307
3. Montz H, Koch KC, Zierz R, et al: The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunology 1991;74:373-379
4. Ikai M, Itoh M, Joh T, et al: Complement plays an essential role in shock following intestinal ischaemia in rats. Clin Exp Immunol 1996;106:156-159
5. van der Graaf F, Koedam JA, Bouma BN: Inactivation of kallikrein in human plasma. J Clin Invest 1983;71:149-158
6. Caliezi C, Wuillemin WA, Zeerleder S, et al: C1-Esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000;52:91-112
7. Kalter ES, Daha MR, Ten Cate JW, et al: Activation and inhibition of Hageman factordependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:1019-1027
8. Wuillemin WA, Minnema M, Meijers JC, et al: Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C1-inhibitor. Blood 1995;85:1517-1526
9. Eriksson H, Sjögren HO: Inhibition of activation of human T lymphocytes by the complement C1 esterase inhibitor. Immunology 1995;86:304-310
10. Liu D, Zhang D, Scafidi J, et al: C1 inhibitor prevents Gram-negative bacterial lipopolysaccharideinduced vascular permeability. Blood 2005;105:2350-2355
11. Dorresteijn MJ, Visser T, Cox LA, et al: C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med 2010;38:2139-2145
12. Frank MM, Jiang H: New therapies for hereditary angioedema: Disease outlook changes dramatically. J Allergy Clin Immunol 2008;121:272-280
13. Gadek JE, Hosea SW, Gelfand JA, et al: Replacement therapy in hereditary angioedema: Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980;302:542-546
14. Bergamaschini L, Cicardi M, Tucci A, et al: C1 INH concentrate in the therapy of hereditary angioedema. Allergy 1983;38:81-84
15. Bork K, Witzke G: Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989;83:677-682
16. Horstick G, Berg O, Heimann A, et al: Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: Doserelated beneficial versus detrimental effects. Circulation 2001;104:3125-3131
17. Caliezi C, Zeerleder S, Redondo M, et al: C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Crit Care Med 2002;30:1722-1728
18. de Zwaan C, Kleine AH, Diris JH, et al: Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. European Heart Journal 2002;23:1670-1677
19. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
20. Laterre PF, Abraham E, Janes JM, et al: ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation. Crit Care Med 2007;35:1457-1463
21. American College of Chest Physicians Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874
22. Baue AE, Faist E, Fry DE (Eds): Multiple Organ Failure: Pathophysiology, Prevention and Therapy. New York, Springer, 2000
23. McNeil BJ, Keller E, Adelstein SJ: Primer on certain elements of medical decision making. N Engl J Med 1975;293:211-215
24. Dolzhenkova L, Lazareva N, Igonin A: Pharmacokinetic-pharmacodynamic analysis of human purified C1-esterase inhibitor in patients with sepsis. Crit Care 2008;12(Suppl 2): P382
25. Igonin A, Lazareva N, Dolzhenkova L: Compliment activity patterns in patients with sepsis after human purified C1-esterase inhibitor infusion. Crit Care 2009;13(Suppl 1): P363
26. Igonin A, Lazareva N, Uvarov VY: C1-esterase inhibitor (C1INH) implication in systemic inflammation in sepsis. Critical Care 2010;14(Suppl 1): P28
27. Hack CE, Ogilvie AC, Eisele B, et al: C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993;19:S19-S28
28. Liu D, Gu X, Scafidi J, et al: N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice. Infect Immun 2004;72:1946-1955
29. Liu D, Lu F, Qin G, et al: C1 inhibitormediated protection from sepsis. J Immunol 2007;179:3966-3972
30. Zwijnenburg PJ, van der Poll T, Florquin S, et al: C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice. J Infect Dis 2007;196:115-123
31. Bauernschmitt R, Böhrer H, Hagl S, et al: Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998;24:635-638
32. Hack CE, Voerman HJ, Eisele B, et al: C1-esterase inhibitor substitution in sepsis. Lancet 1992;339:378
33. Fronhoffs S, Luyken J, Steuer K, et al: The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Med 2000;26:1566-1570